相似文献
1
Isoniazid-resistant tuberculosis: A problem we can no longer ignore.
PLoS Med. 2020 Jan 21;17(1):e1003023. doi: 10.1371/journal.pmed.1003023. eCollection 2020 Jan.
2
Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data.
PLoS Med. 2020 Jan 21;17(1):e1003008. doi: 10.1371/journal.pmed.1003008. eCollection 2020 Jan.
3
Multidrug-resistant and heteroresistant Mycobacterium tuberculosis and associated gene mutations in Ethiopia.
Int J Infect Dis. 2015 Oct;39:34-8. doi: 10.1016/j.ijid.2015.06.013. Epub 2015 Jun 25.
4
Prevalence and outcome of isoniazid-monoresistant tuberculosis at a university hospital in Saudi Arabia.
Saudi Med J. 2021 Jun;42(6):636-642. doi: 10.15537/smj.2021.42.6.20200832.
5
The impact of improved detection and treatment of isoniazid resistant tuberculosis on prevalence of multi-drug resistant tuberculosis: A modelling study.
PLoS One. 2019 Jan 24;14(1):e0211355. doi: 10.1371/journal.pone.0211355. eCollection 2019.
6
Molecular detection of multidrug resistance pattern and associated gene mutations in M. tuberculosis isolates from newly diagnosed pulmonary tuberculosis patients in Addis Ababa, Ethiopia.
PLoS One. 2020 Aug 4;15(8):e0236054. doi: 10.1371/journal.pone.0236054. eCollection 2020.
7
Drug-resistance of Mycobacterium tuberculosis in Patras, Greece.
Monaldi Arch Chest Dis. 2004 Jan-Mar;61(1):65-70.
8
Global burden of drug-resistant tuberculosis in children: a mathematical modelling study.
Lancet Infect Dis. 2016 Oct;16(10):1193-1201. doi: 10.1016/S1473-3099(16)30132-3. Epub 2016 Jun 21.
9
Time to review treatment of isoniazid-resistant tuberculosis?
Lancet Infect Dis. 2017 Feb;17(2):127-128. doi: 10.1016/S1473-3099(16)30381-4. Epub 2016 Nov 17.
10
Multidrug- and isoniazid-resistant tuberculosis in three high HIV burden African regions.
Int J Tuberc Lung Dis. 2013 Aug;17(8):1036-42. doi: 10.5588/ijtld.12.0842.
引用本文的文献
1
Factors associated with unfavourable treatment outcomes among patients with Multidrug-resistant Tuberculosis receiving outpatients care.
Sci Rep. 2025 Aug 4;15(1):28335. doi: 10.1038/s41598-025-13227-5.
2
Drug resistance profile of Mycobacterium tuberculosis complex isolated from pulmonary tuberculosis patients and their household contacts in central Ethiopia.
BMC Infect Dis. 2025 Jun 20;25(1):806. doi: 10.1186/s12879-025-11220-x.
3
Extrapulmonary tuberculosis in Africa: Molecular analysis of clinical specimens of suspected cases in Northern Ghana.
Public Health Chall. 2024 Feb 14;3(1):e160. doi: 10.1002/puh2.160. eCollection 2024 Mar.
4
Sudapyridine (WX-081) inhibits by targeting ATP synthase and upregulating host innate immunity.
mSphere. 2025 Jun 25;10(6):e0014925. doi: 10.1128/msphere.00149-25. Epub 2025 May 21.
5
The risk of rifampicin-resistant TB after drug-susceptible TB treatment.
IJTLD Open. 2025 Mar 12;2(3):173-175. doi: 10.5588/ijtldopen.24.0552. eCollection 2025 Mar.
6
Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis.
Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0035724. doi: 10.1128/aac.00357-24. Epub 2024 Sep 30.
7
Drug resistance profiles of clinical isolates by genotype MTBDRplus line probe assay in Zambia: findings and implications.
JAC Antimicrob Resist. 2024 Jul 25;6(4):dlae122. doi: 10.1093/jacamr/dlae122. eCollection 2024 Aug.
8
A 10-year review of isoniazid-resistant TB management in Uzbekistan 2009-2020.
IJTLD Open. 2024 Jul 1;1(7):285-291. doi: 10.5588/ijtldopen.23.0533. eCollection 2024 Jul.
9
The Hidden Epidemic of Isoniazid-Resistant Tuberculosis in South Africa.
Ann Am Thorac Soc. 2024 Oct;21(10):1391-1397. doi: 10.1513/AnnalsATS.202312-1076OC.
10
Spatial pattern of isoniazid-resistant tuberculosis and its associated factors among a population with migrants in China: a retrospective population-based study.
Front Public Health. 2024 Mar 6;12:1372146. doi: 10.3389/fpubh.2024.1372146. eCollection 2024.
本文引用的文献
1
Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data.
PLoS Med. 2020 Jan 21;17(1):e1003008. doi: 10.1371/journal.pmed.1003008. eCollection 2020 Jan.
2
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.
Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-e142. doi: 10.1164/rccm.201909-1874ST.
3
Tackling drug-resistant tuberculosis: we need a critical synergy of product and process innovations.
Int J Tuberc Lung Dis. 2019 Jul 1;23(7):774-782. doi: 10.5588/ijtld.18.0715.
4
Precision medicine and public health interventions: tuberculosis as a model?
Lancet Public Health. 2019 Aug;4(8):e374. doi: 10.1016/S2468-2667(19)30130-6.
5
Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues.
Nat Rev Microbiol. 2019 Sep;17(9):533-545. doi: 10.1038/s41579-019-0214-5.
6
What will it take to eliminate drug-resistant tuberculosis?
Int J Tuberc Lung Dis. 2019 May 1;23(5):535-546. doi: 10.5588/ijtld.18.0217.
7
Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.
Lancet Respir Med. 2018 Apr;6(4):265-275. doi: 10.1016/S2213-2600(18)30078-X.
8
Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis.
Lancet Infect Dis. 2017 Feb;17(2):223-234. doi: 10.1016/S1473-3099(16)30407-8. Epub 2016 Nov 17.
9
Detection of Isoniazid-, Fluoroquinolone-, Amikacin-, and Kanamycin-Resistant Tuberculosis in an Automated, Multiplexed 10-Color Assay Suitable for Point-of-Care Use.
J Clin Microbiol. 2016 Dec 28;55(1):183-198. doi: 10.1128/JCM.01771-16. Print 2017 Jan.
10
Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.
Lancet Infect Dis. 2016 Oct;16(10):1185-1192. doi: 10.1016/S1473-3099(16)30190-6. Epub 2016 Jul 7.
Zotero 插件